Verification of a decision analytic model assumption using real-world practice data: implications for the cost effectiveness of cyclo-oxygenase 2 inhibitors (COX-2s).
Valuck
Robert
R
D003362:Cost-Benefit Analysis; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects / Q000191:economics*; D003661:Decision Support Techniques; D016527:Drug Costs; D006801:Humans; D008329:Managed Care Programs / Q000706:statistics & numerical data; D017059:Models, Econometric; D015203:Reproducibility of Results; D012107:Research Design / Q000592:standards*; D016896:Treatment Outcome
D016861:Cyclooxygenase Inhibitors